Clinical medicine profile
Lomefloxacin
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- A relatively high incidence of phototoxic reactions has been seen in patients taking lomefloxacin.
- Patients should be advised to avoid exposure to sunlight during, and for a few days after, lomefloxacin therapy, and to stop the drug immediately if phototoxicity occurs.
- Risk of phototoxicity may be reduced by taking lomefloxacin in the evening.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Usual dose is 400 mg OD for 10 to 14 days. A dose of 400 mg OD x 3/7 is suitable in women with acute uncomplicated cystitis.For surgical infection prophylaxis a single 400-mg dose is given 1 to 6 hours before the procedure.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- E.N.T., UTI, RTI, skin and soft tissues, bone, joint, GI, intra-abdominal, pelvic and severe infections, gonorrhoea.
- Clinical selection for Lomefloxacin should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Therapeutic agent (verify pharmacological class).
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- High incidence of photosensitivity, local irritation at the site of injection, GI disturbances, dizziness, headache, tremor, confusion, convulsions, rashes, blurred vision, psychotic reactions, impaired vision, impaired taste and smell sensation, Stevens-Johnson syndrome, hot flushes, skin rashes, migraine.
Drug interactions
Open multi-drug checker ↗- Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
- Document allergy status and key interactions.
Mechanism & disposition
Interferes with bacterial DNA synthesis by inhibiting topoisomerase II [DNA gyrase] and topoisomerase IV.
Read complete mechanism
Interferes with bacterial DNA synthesis by inhibiting topoisomerase II [DNA gyrase] and topoisomerase IV. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.